Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.

Nature medicine - 7 Aug 2011

Liu Pixu, Cheng Hailing, Santiago Stephanie, Raeder Maria, Zhang Fan, Isabella Adam, Yang Janet, Semaan Derek J, Chen Changzhong, Fox Edward A, Gray Nathanael S, Monahan John, Schlegel Robert, Beroukhim Rameen, Mills Gordon B, Zhao Jean J

Abstract excerpt

PIK3CA gain-of-function mutations are a common oncogenic event in human malignancy, making phosphatidylinositol 3-kinase (PI3K) a target for cancer therapy. Despite the promise of targeted therapy, resistance often develops, leading to treatment failure. To elucidate mechanisms of resistance to PI3K-targeted therapy, we constructed a mouse model of breast cancer conditionally expressing human PIK3CA(H1047R)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blotting, Western
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Mammary Neoplasms, Experimental

Share to Mutation, Missense

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-met

Share to Proto-Oncogene Proteins c-myc

Source

Open in PubMed Open full text

Identifiers

PMID: 21822287
DOI: 10.1038/nm.2402
PMCID: PMC3169724

Genes

MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.PMID 21822287Read ↗

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesSemantic proximity Read ↗

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.Semantic proximity Read ↗

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.Semantic proximity Read ↗

Conditional Loss of ErbB3 Delays Mammary Gland Hyperplasia Induced by Mutant PIK3CA without Affecting Mammary Tumor Latency, Gene Expression, or SignalingSemantic proximity Read ↗

Elevated PI3K signaling drives multiple Breast Cancer subtypesSemantic proximity Read ↗

Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.Semantic proximity Read ↗

Genetically engineered mouse models of PI3K signaling in breast cancerSemantic proximity Read ↗

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.Semantic proximity Read ↗

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data.Semantic proximity Read ↗

Modeling the MYC-driven normal-to-tumour switch in breast cancerSemantic proximity Read ↗

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancerSemantic proximity Read ↗

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.